FLAGYL ER Drug Patent Profile
✉ Email this page to a colleague
When do Flagyl Er patents expire, and what generic alternatives are available?
Flagyl Er is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in FLAGYL ER is metronidazole. There are eighteen drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the metronidazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Flagyl Er
A generic version of FLAGYL ER was approved as metronidazole by TEVA PHARMS USA on November 6th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FLAGYL ER?
- What are the global sales for FLAGYL ER?
- What is Average Wholesale Price for FLAGYL ER?
Summary for FLAGYL ER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 172 |
| Clinical Trials: | 74 |
| Patent Applications: | 1,830 |
| DailyMed Link: | FLAGYL ER at DailyMed |
Recent Clinical Trials for FLAGYL ER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Leiden University Medical Center | Phase 4 |
| University of North Carolina, Chapel Hill | Phase 2 |
| University of Amsterdam | Phase 2 |
US Patents and Regulatory Information for FLAGYL ER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | FLAGYL ER | metronidazole | TABLET, EXTENDED RELEASE;ORAL | 020868-001 | Nov 26, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FLAGYL ER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | FLAGYL ER | metronidazole | TABLET, EXTENDED RELEASE;ORAL | 020868-001 | Nov 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FLAGYL ER
See the table below for patents covering FLAGYL ER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 69526434 | ⤷ Sign Up | |
| China | 1139382 | ⤷ Sign Up | |
| Australia | 1596795 | ⤷ Sign Up | |
| Portugal | 744947 | ⤷ Sign Up | |
| Australia | 682248 | ⤷ Sign Up | |
| South Korea | 100368769 | ⤷ Sign Up | |
| Brazil | 9506662 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FLAGYL ER
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0328535 | 96C0021 | Belgium | ⤷ Sign Up | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
